FCMB Group H1’20 Earnings Release – Profits jump 29% y/y amid strong earnings growth

Must Read

List of United Bank for Africa (UBA) Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number that usually identifies both the bank and the branch where an account is held. The sort...

List of Access Bank Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number which usually identifies both the bank and the branch where an account is...

List of First Bank of Nigeria Sort Codes in Nigeria

The sort code is a number that usually identifies both the bank and the branch where an account is held. The sort...
- Advertisement -

Half-year profits soar despite economic woes

FCMB recently released its H1’20 results, reporting a 9% y/y growth in Gross Earnings to ₦98.2 billion, 3% ahead of our estimate. This was mainly due to an 8% y/y growth in Interest Income to ₦76.1 billion driven by a 15% growth in income from investment securities, and a 14% y/y jump in Non-Interest Income to ₦22.0 billion.

Net Interest Income was also up 17% y/y, thanks to a 3% drop in Interest Expense amid a favourable yield environment and lower Interest paid on deposits. However, the bank recorded a significant rise in Loan Loss Provisions as expected, coming in at ₦7.7 billion (+41% y/y), while Operating Expenses grew by 11% to ₦48.6 billion.

Overall, this led to a 26% y/y growth in PBT, which came in at ₦11.1 billion, 2% above our estimate, while PAT came in 29% higher at ₦9.7 billion, giving us a basic EPS of ₦0.49.

Pandemic drag fails to materialize in Q2

Despite the dip in economic activity caused by the shutdowns in some Nigerian states at the start of Q2’20, FCMB performed better than expected across some key line items during the quarter.

The bank reported a 3% q/q increase in Non-Interest Income to ₦11.2 billion, thanks in part to a 32% increase in foreign exchange gains. This meant that whilst Net Interest Income declined by 4% q/q (22.3 billion) and provisions went up by 11% to ₦4.0 billion, PBT actually increased by 4% q/q to ₦5.6 billion.

Read Also:  EFCC Arraigns FCMB Sales Agent Director For Defrauding Customer 1,000,000
- Advertisement -

The bank also reported a 21% YTD growth in Loans and Advances, with a further ₦30 billion added in Q2 alone (a 4% q/q increase). Furthermore, the bank reported an 11% q/q rise in deposits to ₦1.1 trillion; diving deeper, we observed a 12% increase in Current Deposits and a 22% q/q increase in savings deposits amounting to a total increase of ₦118.2 billion, whilst the more expensive Term Deposits declined by 5% or ₦12.3 billion.

We believe this bodes well for the bank’s Interest Expenses going forward and expect Interest Expenses in the coming quarters to remain in decline.

Target Price revised to ₦2.66 (Previous: ₦2.59)

With FCMB’s H1 performance coming in better than expected, we have adjusted our FY’20 expectations while remaining cautious due to the ongoing pandemic. Firstly, we increased our FY Net Interest Income projection to ₦80.9 billion (Previous: ₦76.5 billion), as a result of tamer interest expense growth and slightly higher Interest Income.

However, we also increased our Operating Expense figure to ₦90.9 billion (Previous: ₦88.4 billion). Thus, we project an FY’20 PBT of ₦20.6 billion (Previous: ₦18.9 billion) and PAT of ₦17.8 billion (Previous: ₦16.6 billion). This gives us an estimated EPS of ₦0.90 and DPS expectation of ₦0.14 (FY’19: ₦0.14). Therefore, we revise our target price to ₦2.66 (Previous ₦2.59) and maintain our BUY rating on the stock.

- Advertisement -

FCMB - BRANDSPUR

VETIVA RESEARCH

- Advertisement -
FCMB Group H1'20 Earnings Release - Profits jump 29% y/y amid strong earnings growth - Brand SpurFCMB Group H1'20 Earnings Release - Profits jump 29% y/y amid strong earnings growth - Brand Spur

Subscribe to BrandSpur Ng

Subscribe for latest updates. Signup to best of brands and business news, informed analysis and opinions among others that can propel you, your business or brand to greater heights.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

FCMB Group H1'20 Earnings Release - Profits jump 29% y/y amid strong earnings growth - Brand SpurFCMB Group H1'20 Earnings Release - Profits jump 29% y/y amid strong earnings growth - Brand Spur

Latest News

DEBx Medical Receives CE Mark Clearance and ISO 13485 Certification for Debrichem(R), a Novel Desiccant Gel for Chemical Debridement to Initiate Healing in Infected,...

  • Debrichem(R) offers a very effective, alternative approach to chronic wound care, initiating healing in more than 90 % of cases after one application[1]
  • CE mark and ISO 13485:2016 certification are important prerequisites for upcoming launches in markets worldwide
  • Chronic wounds affect 1 - 2 % of developed countries' populations,[2] unsuccessful treatment may lead to enlargement of the wound, bone involvement or in the worst case, amputation[3]
  • Debrichem soon to be launched in Europe, Hong Kong, South Africa, New Zealand and Australia


ROTTERDAM, THE NETHERLANDS - EQS Newswire - 25 February 2021 - DEBx Medical, the Dutch medical technology company revolutionizing the management of chronic wounds, is excited to highlight today the successful completion of the CE conformity assessment procedure for Debrichem(R). The innovative topical agent offers a superior alternative to surgical debridement, the current standard of care. Debrichem can now carry the CE mark for a medical device class IIb and has also been awarded ISO 13485:2016 certification. These certifications endorse the quality and safety of Debrichem to treat a high unmet medical need and the strength of the DEBx Medical team to achieve this quickly even in such difficult times. DEBx Medical plans first to launch Debrichem in Europe, South Africa as well as Hong Kong, New Zealand and Australia through a network of distribution partners; other markets will follow. DEBx Medical has started consultations with the FDA about the pathway to approval earlier this year.

Debrichem is a topical desiccant gel for chemical wound debridement used for the treatment of chronic infected and/or necrotic wounds. This novel product desiccates (dehydrates) the biofilm and the pathogens in the wound bed, debriding the biofilm chemically instead of surgically. Surrounding healthy skin is not affected.[4] The data underlying the CE mark approval show that, after a one-time 60-second application, more than 90 % of wounds result in full granulation,1 an important step in the healing process.[5] Due to its fast action and applicability outside the surgery room, Debrichem can easily be integrated within standard wound care procedures.4

Read Also:  Sunu Assurances Nigeria Proposes Share Capital Reconstruction

"Being granted the CE mark and ISO 13485 certification for Debrichem in less than two years after founding DEBx Medical is an exciting and important milestone. I am proud of our achievements and would like to thank the whole team involved in this huge effort," said Dr. Bertus Quint, founding CEO of DEBx Medical. "Chronic wounds are painful and debilitating and patients have very limited options for healing. With Debrichem, we set out to significantly improve this situation which is frustrating for healthcare professionals and patients alike. We believe that Debrichem has the potential to meaningfully improve health outcomes and quality of life for millions of patients worldwide."

"In my day-to-day work, I experience the patients' despair associated with chronic wounds and the doctors' frustration with their inability to provide patients long-term healing. With the current COVID-19 pandemic, the situation has been exacerbated: many of our patients are in high-risk groups - elderly, diabetic or chronic cardiovascular patients - who now cannot go to the hospital for their urgently needed treatment," said David L. Helfet, MD, Professor of Orthopaedic Surgery, Weill Cornell Medical College and Hospital for Special Surgery, New York Presbyterian Hospital. "The major advantage of Debrichem is that with a relatively simple, quick, one time application it destroys the biofilm. Removing the biofilm is absolute key to get chronic wounds to heal. Debrichem is an important step forward in the management of chronic wounds and will find its place in the standard of care in a very short time. It may even have the potential to become the new gold standard for debridement in chronic wound care."

Chronic wounds are defined as wounds that have not healed, at least in part, after 4 to 12 weeks.[6] Physiologically, healing of chronic wounds is corrupted, among other factors, by excess inflammation and a recurrent or persistent, if not drug-resistant, microbial infection, often in the biofilm on a wound bed.4 The current gold standard treatment, maintenance surgical debridement, is a painful procedure performed in a sterile environment. Surgical debridement does not reliably initiate healing of the wound but can be part of an extensive wound management program requiring patients to repeatedly come into the hospital. Not surprisingly, general quality of life is impaired in patients with chronic wounds.6 Chronic wounds are estimated to have a prevalence of up to 2 % in the general population.[7] The wound etiology has an impact on outcome, arterial ulcers and venous leg ulcers are notoriously difficult to heal. Chronic wounds are also a common comorbidity of diabetes,[8] 13 % of patients with diabetes in North America to 17 % in Belgium are suffering from chronic wounds.[9] The burden of chronic wounds to healthcare systems and society around the world is substantial, exacerbated by the high rate of amputation in especially diabetic patients which is close to 34 % for diabetic foot ulcers.8 In the UK alone, chronic wounds generated costs of GBP 5.6 bn in 2018. The total wound care costs in the UK increased annually by 8 - 9 % with chronic wounds accounting for the largest share.[10]

References
[1] Cogo A et al., J Wound Care 2020;29(Sup7b):63-64. https://doi.org/10.12968/jowc.2020.29.Sup7b.1
[2] Nussbaum SR et al., Value Health 2018;21:27-32. https://doi.org/10.1016/j.jval.2017.07.007
[3] Strohal R et al., J Wound Care 2013; 22 (Suppl. 1): S1-S52. https://doi.org/10.12968/jowc.2013.22.Sup1.S1
[4] Cogo A et al., Wounds 2021;33:1-8. https://www.woundsresearch.com/article/restarting-healing-process-chronic-wounds-using-novel-desiccant-prospective-case-series
[5]http://www.shieldhealthcare.com/community/popular/2015/12/18/how-wounds-heal-the-4-main-phases-of-wound-healing/
[6] Olsson M et al., Wound Repair Regen 2019;27(1):114-125. https://doi.org/10.1111/wrr.12683
[7] Martinengo L et al., Ann Epidemiol 2019;29:8-15. https://doi.org/10.1016/j.annepidem.2018.10.005
[8] McCosker L et al., Int Wound J 2019;16:84-95. https://doi.org/10.1111/iwj.12996
[9] Zhang P et al., Ann Med 2017;49:106-116. https://doi.org/10.1080/07853890.2016.1231932
[10] Guest JF et al., BMJ Open 2020;10:e045253. https://doi.org/10.1136/bmjopen-2020-045253


The issuer is solely responsible for the content of this announcement.


About Debrichem(R)

Debrichem(R) is a disruptive new treatment option to address the infection in chronic wounds. The topical agent offers a superior alternative to surgical debridement, the current standard of care. Debrichem has been demonstrated to remove the biofilm and the pathogens from the wound bed that disrupt the onset of the natural healing process. Out of the more than 1.000 patients treated so far, more than 90 % of chronic wounds started to heal after only one treatment with Debrichem.4 The product is applied in a fast and simple, non-invasive procedure. Healthcare professionals should always consider using local anesthetics when applying the treatment. Debrichem can be used outside a surgical environment which can be particularly useful in situations, such as during the COVID-19 pandemic, where patients cannot get to hospitals to undergo surgery, avoiding long-term complications like amputation. Debrichem will be sold through a worldwide network of distributors, with the first market launches expected in Q1 2021.


About DEBx Medical

DEBx Medical B.V. is a Dutch medical technology company dedicated to revolutionizing the management of chronic wounds by enabling their healing, thereby improving the outcomes for millions of patients. DEBx Medical supports doctors and their patients from diagnosis through treatment, follow-up care, and maintenance of a healthy wound bed. The Company focuses its pipeline on targeting pathogens that corrupt wound healing, aiming to deliver affordable and effective treatment approaches that can easily be applied and implemented in daily clinical practice. Debrichem(R), DEBx Medical's first product, received a CE mark in early 2021 and will be launched in markets around the world. Debrichem offers a disruptive approach to debridement that has been demonstrated to enable healing of chronic wounds in more than 90 % of cases.

FCMB Group H1'20 Earnings Release - Profits jump 29% y/y amid strong earnings growth - Brand Spur
- Advertisement -
BrandsPur Weekly Cartoons
- Advertisement -FCMB Group H1'20 Earnings Release - Profits jump 29% y/y amid strong earnings growth - Brand SpurFCMB Group H1'20 Earnings Release - Profits jump 29% y/y amid strong earnings growth - Brand Spur